Clinical trials: Epilepsy; Seizure
Epilepsy, Complex Partial
A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601
This study is designed to provide ganaxolone to those patients deriving significant benefit from current treatment in protocol 1042-0601.
- Trial name
- 0602 (NCT01002820)
- Testing
- ganaxolone
- Where
- 7 sites in United States
- Volunteers
- 11 people
- Sponsor
- Marinus Pharmaceuticals
Acute Repetitive Seizures
Repeat-Dose Pharmacokinetics Study of NRL-1 in Epilepsy Subjects
This study evaluates the pharmacokinetic and safety of NRL-1 in epilepsy subjects. Subjects will receive a single intranasal dose of NRL-1 of either 5 mg, 10 mg, 15 mg or 20 mg and will be based on the subject's body weight.
- Trial name
- NCT02724423
- Testing
- NRL-1
- Where
- 4 sites in United States
- Volunteers
- 57 people
- Sponsor
- Neurelis, Inc.
Epilepsy
Seizure Detection and Automatic Magnet Mode Performance Study
The purpose of this study is to confirm cardiac-based seizure detection in Cyberonics Model 106 VNS Therapy System.
- Trial name
- E-36 (NCT01325623)
- Testing
- Model 106 VNS Therapy System
- Where
- 14 sites in Belgium, Germany and 3 more
- Volunteers
- 31 people
- Sponsor
- Cyberonics, Inc.
Drug Resistant Epilepsy, Drop Seizures
Novel Helmet Design in Patients With Seizures
This is a two-part study that aims to determine the reliability and safety of the use of the Hövding inflatable helmet in seizures, as evidenced by the deployment of the helmet during seizures, and qualitative patient reporting.
- Conditions
- Drug Resistant Epilepsy, Drop Seizures, Generalized Tonic Clonic Seizure, Complex Partial Seizure
- Trial name
- NCT03443388
- Testing
- Hövding inflatable helmet
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Michael A. Gelfand, MD, PhD
Epilepsy
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
The main purpose of this study is to evaluate the effectiveness of the study drug lacosamide (200-600 mg/day) when added to a stable dose of levetiracetam (1000-3000 mg/day) with withdrawal of the concomitant sodium channel…
- Trial name
- VERVE (NCT01484977)
- Testing
- Lacosamide
- Where
- 54 sites in United States, Australia and 7 more
- Volunteers
- 120 people
- Sponsor
- UCB Pharma
Epilepsy, Epilepsy in Children
An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE
To assess the long-term safety and tolerability of XEN496 in pediatric subjects with KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE) who had participated in the primary study (XPF-009-301).
- Conditions
- Epilepsy, Epilepsy in Children, Epilepsy; Seizure, Disease
- Trial name
- EPIK-OLE (NCT04912856)
- Testing
- XEN496
- Where
- 4 sites in United States, Australia and 1 more
- Volunteers
- 8 people
- Sponsor
- Xenon Pharmaceuticals Inc.
Epilepsy
A Study to Look at the Efficacy and Safety of Keppra® Extended Release Formulation - XR
This is a safety and efficacy study of Keppra® extended release formulation - XR in patients with epilepsy.
- Trial name
- NCT00368069
- Testing
- Keppra® extended release formulation - XR
- Where
- 34 sites in Brazil, Finland and 5 more
- Volunteers
- 158 people
- Sponsor
- UCB Pharma
Epilepsy
Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters
The purpose of this study is to examine the long-term safety and tolerability of USL261 in the treatment of seizure clusters.
- Trial name
- NCT01529034
- Testing
- USL261
- Where
- 58 sites in United States, Australia and 8 more
- Volunteers
- 175 people
- Sponsor
- UCB Biopharma S.P.R.L.
Epilepsy
Progesterone vs Placebo Therapy for Women With Epilepsy
The purpose of this investigation was to determine if cyclic adjunctive progesterone supplement is superior to placebo in the treatment of intractable seizures in women with and without catamenial epilepsy.
- Trial name
- NCT00029536
- Testing
- Progesterone Lozenges
- Where
- 15 sites in United States, Canada
- Volunteers
- 294 people
- Sponsor
- Beth Israel Deaconess Medical Center
Epilepsy
Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures
This study will evaluate the efficacy and safety of brivaracetam at doses of 100 and 200mg/day compared to placebo as adjunctive treatment in adult focal epilepsy subjects with partial onset seizures not fully controlled despite…
- Trial name
- BRITE (NCT01261325)
- Testing
- Brivaracetam, Antiepileptic drugs with market authorization available per country
- Where
- 207 sites in United States, Austria and 26 more
- Volunteers
- 768 people
- Sponsor
- UCB Pharma
Epilepsy, Partial
Follow-up Study of L059 (Levetiracetam) in Epileptic Patients With Partial Onset Seizures by Open Label Method
The safety and efficacy of L059 was evaluated in patients who completed "N165 Clinical Trial of L059". They received L059 at a daily dose from 1,000 mg to 3,000 mg in addition to their standard concomitant AEDs
- Trial name
- NCT00160615
- Testing
- Levetiracetam
- Volunteers
- 154 people
- Sponsor
- UCB Japan Co. Ltd.
Epilepsy
Study in Pediatric Subjects With Epilepsy
This is an open-label study to evaluate the pharmacokinetics, safety and tolerability of ezogabine/retigabine in subjects aged 12 years to less than 18 years with uncontrolled partial onset seizures or Lennos-Gastaut syndrome.
- Trial name
- NCT01494584
- Testing
- ezogabine/retigabine
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- GlaxoSmithKline
Epilepsy
RNS® System Pivotal Study
The RNS® System Pivotal study is designed to assess safety and demonstrate that the RNS® System is effective as an adjunctive (add-on) therapy in reducing the frequency of seizures in individuals 18 years of age or older with…
- Trial name
- NCT00264810
- Testing
- RNS® System implantation, RNS® System responsive stimulation
- Where
- 32 sites in United States
- Volunteers
- 240 people
- Sponsor
- NeuroPace
Epilepsy
Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy
This study is intended to provide evidence that zonisamide is safe and effective in the treatment of myoclonic seizures. The total planned trial duration will be 6.5 months.
- Trial name
- NCT00693017
- Testing
- Zonisamide
- Where
- 72 sites in Australia, Croatia and 11 more
- Volunteers
- 10 people
- Sponsor
- Eisai Limited
Epilepsy, Lennox-Gastaut Syndrome
A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
To evaluate the efficacy of GWP42003-P as adjunctive treatment in reducing the number of drop seizures when compared with placebo, in participants with Lennox-Gastaut Syndrome (LGS).
- Trial name
- GWPCARE4 (NCT02224690)
- Testing
- GWP42003-P 20 mg/kg/day Dose
- Where
- 24 sites in United States, Netherlands and 1 more
- Volunteers
- 171 people
- Sponsor
- Jazz Pharmaceuticals
Epilepsy; Seizure, Neuromuscular Diseases
North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2
The "North Carolina Clinical Genomic Evaluation by Next-gen Exome Sequencing, 2 (NCGENES 2)" study is part of a larger consortium project investigating the clinical utility, or net benefit of an intervention on patient and family…
- Conditions
- Epilepsy; Seizure, Neuromuscular Diseases, Brain Malformation, Intellectual Disability
- Trial name
- NCGENES2 (NCT03548779)
- Testing
- Pre-visit prep, usual care + exome seq
- Where
- 3 sites in United States
- Volunteers
- 548 people
- Sponsor
- University of North Carolina, Chapel Hill
Epilepsy
Trial Evaluating the Efficacy and Safety of Perampanel Added to Monotherapy in Participants With Partial Onset Seizures With or Without Secondary Generalization
This is a multi-center, open-label, single-arm, phase 4 study to evaluate the efficacy of perampanel added to monotherapy for partial onset seizures with or without secondarily generalized seizures (total seizures).
- Trial name
- NCT02726074
- Testing
- Perampanel
- Where
- 6 sites in South Korea
- Volunteers
- 106 people
- Sponsor
- Eisai Korea Inc.
Anxiety Disorder, Seizures
Buspirone Therapy for Localized Epilepsy
Background: Buspirone is a drug that is approved for the treatment of anxiety in adults. Studies suggest that buspirone might act on parts of the brain that can increase certain levels of brain activity.
- Conditions
- Anxiety Disorder, Seizures, Epilepsy, Partial Epilepsy
- Trial name
- NCT01496612
- Testing
- Buspirone
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Partial Seizures
Pregabalin Versus Levetiracetam In Partial Seizures
This study will compare pregabalin and levetiracetam in patients with partial seizures. It will also evaluate the safety and tolerability of pregabalin and levetiracetam in these patients.
- Trial name
- NCT00537238
- Testing
- pregabalin, levetiracetam
- Where
- 72 sites in Belgium, Bulgaria and 19 more
- Volunteers
- 509 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Drug Resistant Partial Onset Seizure
A Two-year Open-label Extension Study of Ganaxolone in Patients With Drug-resistant Partial-onset Seizures
A follow-on, two-year open-label extension study of ganaxolone as add-on therapy in adult patients with drug-resistant partial-onset seizures
- Trial name
- NCT02519439
- Testing
- ganaxolone
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Marinus Pharmaceuticals